Jordi Ochando, Spain

Instituto de Salud Carlos III

My laboratory investigates the origin, development and immune regulatory functions of myeloid cells in organ transplantation. As negative regulators of the immune response, myeloid cells represent a novel therapeutic approach to promote organ transplant acceptance. We have recently evaluated a targeted therapeutic delivery system in which drug-loaded nanoparticles that specifically target myeloid cells induce long-term allograft acceptance with minimal immunosuppressive drug usage. As this innovative approach combines existing FDA approved agents that target myeloid cells in vivo, the pre-clinical development of this technology has an immediate path to translation.


Lectures by Jordi Ochando


Committees

Committee Role Section
Scientific Program Committee: Basic and Translational Sciences Member

© 2017 TTS2018